Cytori Therapeutics (CYTX) Given a $5.00 Price Target at Maxim Group

Cytori Therapeutics (NASDAQ:CYTX) has been assigned a $5.00 price objective by equities research analysts at Maxim Group in a research report issued to clients and investors on Monday. The brokerage presently has a “buy” rating on the biotechnology company’s stock.

CYTX has been the topic of several other reports. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th.

Shares of Cytori Therapeutics (NASDAQ CYTX) remained flat at $$0.40 during mid-day trading on Monday. 1,627,654 shares of the company’s stock were exchanged, compared to its average volume of 3,251,161. Cytori Therapeutics has a 1-year low of $0.22 and a 1-year high of $2.13. The stock has a market capitalization of $14.28, a price-to-earnings ratio of -0.44 and a beta of 3.21.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. The firm had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.04 million. During the same period in the previous year, the business earned ($0.26) EPS. analysts expect that Cytori Therapeutics will post -0.62 EPS for the current year.

In related news, major shareholder Bank Sa Swissquote sold 100,000 shares of Cytori Therapeutics stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the sale, the insider now owns 5,496,655 shares of the company’s stock, valued at approximately $2,088,728.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.90% of the stock is owned by insiders.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Sabby Management LLC increased its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,626,807 shares of the biotechnology company’s stock after buying an additional 355,504 shares during the period. Sabby Management LLC owned 4.69% of Cytori Therapeutics worth $1,789,000 as of its most recent filing with the SEC. Institutional investors own 7.39% of the company’s stock.

WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/22/cytori-therapeutics-cytx-given-a-5-00-price-target-at-maxim-group.html.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply